TG Therapeutics' Phase 1 subcutaneous Briumvi results show strong safety and bioavailability, boosting confidence in its clinical program.

TG Therapeutics announced positive Phase 1 results for its subcutaneous Briumvi, demonstrating good bioavailability, safety, and tolerability. This outcome reduces risks for the company's key clinical development program, with Phase 3 topline data expected by late 2026 or early 2027. The company also raised its 2026 U.S. sales guidance for intravenous Briumvi to $885–900 million, reflecting improved growth prospects. Key risks include potential Phase 3 underperformance and competition from other treatments in multiple sclerosis.